openPR Logo
Press release

Biosimilars Market Report- Key Company Profiles, Types, Applications and Forecast to 2027

10-06-2021 02:31 PM CET | Health & Medicine

Press release from: ReportsnReports

The Biosimilars Market research report includes market objectives and scopes during the projected period by highlighting key market segments and leading players. Biosimilars Market also has years considered during the research methodology of the market. The Biosimilars Market report offers an executive summary of the maker by covering industry trends by focusing on top market trends, the market size by regions, and global market size. Biosimilars Market also provides region-wise and country-wise growth rates of the Biosimilars Market.

Get a FREE PDF Sample Copy of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=270786

Top Companies Mentioned in this Report- Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany), Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

The report analyzes the biosimilars market by product, type of manufacturing, indication, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is driven mainly by the increasing number of product launches/approvals, rising incidences of cancer diseases.

Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market.

Discount on this Full Report @ https://www.reportsnreports.com/purchase.aspx?name=270786

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one, or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the services of the top players in the biosimilars market Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market Market Development: Detailed information about emerging markets. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market.
Table of Contents in this Report-

1 Introduction
1.1 Objectives of The Study
1.2 Market Definition
1.3 Market Scope
1.4 Years Considered For The Study
1.5 Currency
1.6 Stakeholders

2 Research Methodology
2.1 Research Data
2.2 Secondary Data
2.2.1 Secondary Sources
2.3 Primary Data
2.3.1 Key Data From Primary Sources
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Growth Forecast
2.4.3 Top-Down Approach
2.5 Market Breakdown And Data Triangulation
2.6 Assumptions For The Study
2.7 Limitations

3 Executive Summary

4 Premium Insights
4.1 Biosimilars Market Overview
4.2 North America: Biosimilars Market, By Product, 2019
4.3 Geographical Snapshot of The Biosimilars Market

5 Regulatory Outlook
5.1 North America
5.1.1 Us
5.1.2 Canada
5.2 Europe
5.3 Asia Pacific
5.3.1 China
5.3.2 India
5.3.3 Japan
5.3.4 South Korea
5.3.5 Australia
5.4 Rest of The World
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Argentina
5.4.4 Saudi Arabia

6 Market Overview
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.1.1 Increasing Demand For Biosimilar Drugs
6.2.1.2 Rising Incidence of Chronic Diseases
6.2.2 Restraints
6.2.2.1 Complexities In Manufacturing
6.2.2.2 Resistance From Biologic Manufacturers
6.2.3 Opportunities
6.2.3.1 Emerging Markets
6.2.3.2 New Indications And The Patent Expiry of Biologic Products
6.2.4 Challenges
6.2.4.1 Stringent Regulatory Requirements
6.2.5 Trends
6.2.5.1 Collaborations For Biosimilar Research And Clinical Trials

7 Biosimilars Market, By Product

and more…

+ 1 888 391 5441
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market Report- Key Company Profiles, Types, Applications and Forecast to 2027 here

News-ID: 2419470 • Views:

More Releases from ReportsnReports

DeviceCon Series 2024 - UK Edition | MarketsandMarkets
DeviceCon Series 2024 - UK Edition | MarketsandMarkets
Future Forward: Redefining Healthcare with Cutting-Edge Devices Welcome to DeviceCon Series 2024 - Where Innovation Meets Impact! Join us on March 21-22 at Millennium Gloucester Hotel, 4-18 Harrington Gardens, London SW7 4LH for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of four conferences that promise to redefine the landscape of innovation in medical and diagnostic devices. Register Now @ https://events.marketsandmarkets.com/devicecon-series-uk-edition-2024/register MarketsandMarkets presents
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Conference Promises New Trends and Insights in Diagnosis
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Confer …
London, March 7, 2024 - MarketsandMarkets is thrilled to announce the eagerly awaited 5th Annual Infectious Disease and Molecular Diagnostics Conference, scheduled to take place on March 21st - 22nd, 2024, at the prestigious Millennium Gloucester Hotel, located at 4-18 Harrington Gardens, London SW7 4LH. This conference promises to be a groundbreaking event, showcasing the latest trends and insights in diagnosis, as well as unveiling cutting-edge technologies that are revolutionizing the
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March 2024| Challenges and Factors affecting in Sterilization of medical devices and more
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March …
MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21-22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays. Enquire Now @ https://events.marketsandmarkets.com/infection-control-sterilization-and-decontamination-conference/ This conference aims to bring together all the stakeholders to discuss the obstacles in achieving
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, Surface and Forecast to 2025
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, S …
The global Breast Augmentation Market in terms of revenue was estimated to be worth $900 million in 2020 and is poised to reach $1,692 million by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of